SCHEMBL19924937

SCHEMBL19924937

COc1ccc(Cn2nc(-c3ccccc3)cc2N)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.74
MAPT P10636 8/20 0.71
MEN1 O00255 7/20 0.71
KMT2A Q03164 7/20 0.71
STAT3 P40763 2/20 0.71
LMNA P02545 2/20 0.71
GAA P10253 2/20 0.61
GALR3 O60755 1/20 0.61
NPY1R P25929 1/20 0.61
NPY2R P49146 1/20 0.61
HTT P42858 2/20 0.59
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
ADORA2A P29274 1/20 0.54
TP53 P04637 1/20 0.52
POLB P06746 1/20 0.52
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2321371 0.85 SMN1; SMN2 (1.00) SMN1; SMN2MAPTMEN1KMT2ASTAT3
SCHEMBL13734555 0.85 MAPT (0.56) SMN1; SMN2MAPTMEN1KMT2ASTAT3
SCHEMBL19926059 0.83 SMN1; SMN2 (0.50) SMN1; SMN2MAPTMEN1KMT2ASTAT3
SCHEMBL29875021 0.83 SMN1; SMN2 (0.50) SMN1; SMN2MAPTMEN1KMT2ASTAT3
SCHEMBL14132905 0.83 SMN1; SMN2 (1.00) SMN1; SMN2MAPTMEN1KMT2ASTAT3
SCHEMBL22632894 0.82 MAPT (0.49) SMN1; SMN2MAPTMEN1KMT2ASTAT3
SCHEMBL3841611 0.81 MAPT (0.70) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL7995817 0.81 MAPT (0.63) SMN1; SMN2MAPTMEN1KMT2ASTAT3
SCHEMBL8889722 0.81 MAPT (0.70) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL19925941 0.80 POLB (0.50) SMN1; SMN2MAPTMEN1KMT2ASTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116283994-B Heterocyclic compounds as MAT2A inhibitors 艾立康药业股份有限公司 2025-01-07 CN disclosed
US-RE49934-E1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2024-04-23 US disclosed
CN-116283994-A Heterocyclic compounds as MAT2A inhibitors 艾立康药业股份有限公司 2023-06-23 CN disclosed
CN-109890822-B Inhibitors of cellular metabolic processes 安吉奥斯医药品有限公司 2022-08-30 CN disclosed
US-11325914-B1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2022-05-10 US disclosed
US-11312722-B2 Hsp90 inhibitors and uses thereof TRUSTEES OF BOSTON UNIVERSITY (US) 2022-04-26 US disclosed
US-20200354373-A1 HSP90 INHIBITORS AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2020-11-12 US disclosed
WO-2020227368-A1 HSP90 INHIBITORS AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2020-11-12 WO disclosed
US-10800782-B2 Inhibitors of cellular metabolic processes Agios Pharmaceutical, Inc. (US) 2020-10-13 US disclosed
US-20190233424-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES SERVIER PHARMACEUTICALS LLC 2019-08-01 US disclosed
EP-3507290-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES Agios Pharmaceuticals, Inc. (US) 2019-07-10 EP disclosed
US-10329298-B2 Inhibitors of cellular metabolic processes AGIOS PHARMACEUTICALS, INC. (US) 2019-06-25 US disclosed
CN-109890822-A INHIBITORS OF CELLULAR METABOLIC PROCESSES 安吉奥斯医药品有限公司 2019-06-14 CN disclosed
US-20180079753-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES SERVIER PHARMACEUTICALS LLC 2018-03-22 US disclosed
US-20180079753-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES SERVIER PHARMACEUTICALS LLC 2018-03-22 US disclosed
WO-2018039972-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES AGIOS PHARMACEUTICALS, INC. (US) 2018-03-08 WO disclosed
WO-2018039972-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES AGIOS PHARMACEUTICALS, INC. (US) 2018-03-08 WO disclosed
WO-2018045071-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES AGIOS PHARMACEUTICALS, INC. (US) 2018-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329298-B2 Inhibitors of cellular metabolic processes MNAT1, MAT2A, PCK2 SMN1; SMN2 2162/4885MAPT 1914/4885MEN1 1624/4885
US-20200354373-A1 HSP90 INHIBITORS AND USES THEREOF HSP90AB1, HSP90B1, HSP90AA1 SMN1; SMN2 4707/4885MAPT 494/4885MEN1 4327/4885
US-20190233424-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES MNAT1, MAT2A, PCK2 SMN1; SMN2 2162/4885MAPT 1914/4885MEN1 1624/4885
US-10800782-B2 Inhibitors of cellular metabolic processes MNAT1, MAT2A, PCK2 SMN1; SMN2 2162/4885MAPT 1914/4885MEN1 1624/4885
US-20180079753-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES MNAT1, MAT2A, PCK2 SMN1; SMN2 2162/4885MAPT 1914/4885MEN1 1624/4885
US-11312722-B2 Hsp90 inhibitors and uses thereof HSP90AB1, HSP90B1, HSP90AA1 SMN1; SMN2 4707/4885MAPT 494/4885MEN1 4327/4885
US-11325914-B1 Inhibitors of cellular metabolic processes MNAT1, MAT2A, PCK2 SMN1; SMN2 2162/4885MAPT 1914/4885MEN1 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.